Company news
Bluenergies Ltd. (TSXV:BLU) news
Bluenergies Ltd. news releases on 6ix. Latest, Oct 1, 2012: BELLUS Health to Present at BioContact in Québec City
Press releases — page 3
BELLUS Health to Present at BioContact in Québec City
October 1, 2012
BELLUS Health Announces Partnership for the Development of BLU8499
September 4, 2012
BELLUS Health Reports Results for Second Quarter Ended June 30, 2012
August 8, 2012
BELLUS Health Receives Milestone Payment from Advanced Orthomolecular Research
June 21, 2012
Bellus Health to Present at Bloom Burton & Co. Healthcare Investor Conference
June 6, 2012
Bellus Health to Present at BioFinance 2012
May 25, 2012
Bellus Health and Pharmascience Announce Closing of $17.25M Transaction
May 25, 2012
BELLUS Health Securityholders Vote in Favour Of $17.25 Million Strategic Transaction with Pharmascience
May 15, 2012
BELLUS Health announces update on the Phase III trial for KIACTA(tm) in AA amyloidosis presented at the XIII International Symposium on Amyloidosis
May 10, 2012
BELLUS Health Announces Share Consolidation and Record Date for Annual and Special Meeting of Securityholders
April 19, 2012
BELLUS Health announces a $17 million strategic partnership and financing with Pharmascience Inc.
April 5, 2012
BELLUS Health reports results for year ended December 31, 2011, and provides update on KIACTA(tm) phase 3 confirmatory study
February 22, 2012
BELLUS Health and Integris Pharma Ltd. enter into exclusive license agreement for VIVIMIND(tm) in Greece and Cyprus
December 1, 2011
OVOS Natural Health Inc. launches VIVIMIND(tm) in Canada
November 28, 2011
BELLUS Health reports results for third quarter ended September 30, 2011, and provides update on VIVIMIND(tm) partnerships
November 9, 2011
BELLUS Health reports results for second quarter ended June 30, 2011
August 10, 2011
Crystal Research Associates Issues Research Report on BELLUS Health Inc.
July 13, 2011
BELLUS HEALTH REPORTS RESULTS FOR FIRST QUARTER ENDED MARCH 31, 2011
June 8, 2011
BELLUS HEALTH DELIVERING ON KEY STRATEGIC PARTNERSHIPS AND KIACTA(tm) PHASE III DEVELOPMENT
May 11, 2011
BELLUS HEALTH ISSUES SHARES IN FINAL PAYMENT FOR THE EXERCISE OF ITS LEASE TERMINATION OPTION
April 7, 2011
BELLUS HEALTH AND THE AGAHAN GROUP ENTER INTO BROAD LICENSE FOR VIVIMIND(tm) IN THE MIDDLE EAST
April 4, 2011
BELLUS HEALTH COMPLETES RESTRUCTURING INITIATIVES WITH REPATRIATION OF INTELLECTUAL PROPERTY TO CANADA
March 31, 2011
BELLUS HEALTH REPORTS RESULTS FOR FOURTH QUARTER AND YEAR ENDED DECEMBER 31, 2010
February 23, 2011
BELLUS HEALTH ANNOUNCES PHASE I RESULTS OF PRODRUG NRM8499 INTENDED FOR THE TREATMENT OF ALZHEIMER'S DISEASE
January 31, 2011
BELLUS HEALTH EXERCISES OPTION TO TERMINATE LEASE
January 14, 2011
ADVANCED ORTHOMOLECULAR RESEARCH ACQUIRES BELLUS HEALTH'S CANADIAN SUBSIDIARY OVOS NATURAL HEALTH
January 4, 2011
Crystal Research Associates Issues Updated Report on BELLUS Health Inc.
December 16, 2010
CELTIC THERAPEUTICS AND BELLUS HEALTH INITIATE CONFIRMATORY PHASE III CLINICAL STUDY FOR KIACTA?, A DRUG CANDIDATE FOR THE TREATMENT OF AA AMYLOIDOSIS
December 15, 2010
BELLUS HEALTH REPORTS RESULTS FOR THIRD QUARTER ENDED SEPTEMBER 30, 2010 AND ANNOUNCES RECEIPT OF US$5 MILLION FROM PARTNER CELTIC THERAPEUTICS
November 10, 2010
BELLUS HEALTH AND FB HEALTH ENTER AGREEMENT FOR BELLUS' VIVIMIND¿ IN ITALY
October 19, 2010
BELLUS HEALTH ANNOUNCES APPOINTMENT OF MARTIN TOLAR, M.D., Ph.D. TO ITS BOARD OF DIRECTORS
October 6, 2010
HEALTH CANADA GRANTS VIVIMIND¿ A NATURAL HEALTH PRODUCT NUMBER
September 30, 2010
Bellus Health reports results for second quarter ended June 30, 2010
August 9, 2010
BELLUS Health Inc.
May 12, 2010
Annual Meeting of Shareholders - BELLUS Health provides update on corporate and product developments
May 12, 2010
BELLUS Health reports results for first quarter ended March 31, 2010
May 12, 2010
/R E P E A T -- BELLUS Health Inc. Annual and Special Meeting of Shareholders May 12, 2010/
May 12, 2010
BELLUS Health Inc. Annual and Special Meeting of Shareholders May 12, 2010
May 11, 2010
BELLUS Health ends NC-503 diabetes development program following results
May 4, 2010
BELLUS Health and Celtic Therapeutics enter agreement for BELLUS' drug candidate KIACTA(TM)
April 29, 2010
BELLUS Health announces launch of NRM8499 Phase I clinical study for the treatment of Alzheimer's disease
April 1, 2010
BELLUS Santé annonce le début de l'essai clinique de phase I sur le NRM8499 pour le traitement de la maladie d'Alzheimer
April 1, 2010
BELLUS Health reports results for fourth quarter and year ended December 31, 2009
February 24, 2010
BELLUS Santé annonce ses résultats pour le quatrième trimestre et l'exercice terminés le 31 décembre 2009
February 24, 2010
Roberto Bellini appointed President and CEO of BELLUS Health - Francesco Bellini to remain as Chairman of the Board; Charles Cavell appointed Deputy Chairman of the Board
December 15, 2009
Roberto Bellini nommé Président et chef de la direction de BELLUS Santé - Francesco Bellini demeure président du conseil; Charles Cavell nommé vice-président du conseil
December 15, 2009
BELLUS Santé annonce ses résultats pour le troisieme trimestre de 2009
November 10, 2009
BELLUS Health reports results for third quarter of fiscal 2009
November 10, 2009
TSX Delisting Review - BELLUS Health Inc. (BLU)
October 21, 2009
BELLUS Health announces results of rights offering
September 8, 2009